Allos reports net loss of $20.

Allos reports net loss of $20.0 million for second-quarter 2010 Allos Therapeutics, Inc . today reported its monetary outcomes and business highlights for the one fourth and six months ended June 30, 2010.S. For the treating patients with relapsed or refractory peripheral T-cell lymphoma . Gross product sales had been $9.0 million and $17.june 30 2 million for the quarter and six months ended, 2010, respectively. Gross revenue in the second one fourth of 2010 elevated by 10 % compared to the first quarter of 2010.

ONC-ATCB 2011/2012 qualification conferred by CCHIT does not represent an endorsement of the certified EHR technology by the U.S. Division of Human and Health Services nor does it promise the receipt of incentive obligations. The clinical quality actions to which Allscripts ED offers been certified consist of: NQF 0371 – Venous Thromboembolism prophylaxis within 24 hoursNQF 0372 – Intensive Care Device Venous Thromboembolism prophylaxisNQF 0373 – Overlapping Anticoagulation therapyNQF 0374 – Platelet Monitoring on Unfractionated HeparinNQF 0375 – Venous Thromboembolism discharge instructionsNQF 0376 – Incidence of potentially preventable Venous ThromboembolismNQF 0435 – Stroke: Discharge on anti-thromboticsNQF 0436 – Ischemic Stroke – Anticoagulation for A-fib/flutterNQF 0437 – Ischemic Stroke – Thrombolytic therapyNQF 0438 – Ischemic or Hemorrhagic stroke – Anti-thrombotic therapyNQF 0439 – Ischemic stroke – Discharge on statinsNQF 0440 – Ischemic or Hemorrhagic Stroke – Stroke educationNQF 0441 – Ischemic or Hemorrhagic Stroke – Rehabilitation assessmentNQF 0495 – Emergency Division Throughput – Arrival to DepartureNQF 0497 – Emergency Department Throughput – Admission to InpatientThe additional software program Allscripts ED relied upon to demonstrate compliance includes: Open Resource Device, and .NET Encryption Check Harness.